Figure 8
From: Flexible Targeting of ErbB Dimers That Drive Tumorigenesis by Using Genetically Engineered T Cells
In vitro antitumor activity of T1E28z+ T cells against breast cancer. (A) 1 × 106 human T cells engineered to express the indicated CARs were cocultivated with confluent breast cancer monolayers, cultured in 24-well (1.9-cm2) plates. After 24 h, nonadherent cells were removed and monolayers were fixed and stained with crystal violet. (B) Four-hour lactate dehydrogenase release cytotoxicity assay in which T1E28z+ or control S28z+ T cells were cultured with BT20 breast cancer cells or ERBBlo 410.4 mammary carcinoma cells. (C) A representative experiment in which T1E28z+ and S28z+ T cells were cultured with BT20 breast cancer cells. After 24 h, IL-2 was added. Restimulation on a confluent BT20 monolayer was performed where indicated by the overhead arrows. T cells were enumerated at the indicated intervals. (D) Transduced T cells were cocultivated in 24-well plates with confluent monolayers or suspension cells as follows: 1) Jurkat (control; 1 × 106 cells); 2) MDA-MB-435; 3) BT20; 4) BT474; 5) MCF7; 6) SKBR3; 7) T47D; 8) medium alone. Supernatants were analyzed for the indicated cytokines after 24 h.